NewsRoom Articles - BioMedWire (BMW)

TuesdayAug 25, 2026 10:00 am

Personalized mRNA Vaccine Prevents Melanoma Recurrence, New Study Finds

A new study whose results are yet to be peer-reviewed has shown that a personalized mRNA vaccine made from the tumor tissue of a patient can prevent the cancer from recurring years after the treatment is given. The study was a joint undertaking by pharmaceutical firms Merck and Moderna. The clinical trial involved giving more than 1,000 patients a combination of an immunotherapy medication called Keytruda after a surgical procedure to remove melanoma, a deadly type of skin cancer. Patients also received Intismeran, a personalized cancer vaccine. The personalized vaccine was produced by extracting tumor samples and formulating the mRNA vaccine for each participant. …

TuesdayAug 25, 2026 9:00 am

Nano-X Imaging Ltd. (NASDAQ: NNOX) Is ‘One to Watch’

The company combines proprietary imaging hardware, FDA-cleared AI applications, cloud software, radiology services and healthcare IT within an end-to-end platform spanning scan, analysis and interpretation. Nanox is expanding its commercial reach through its U.S. commercial activities and collaboration with healthcare organizations. First-quarter 2026 revenue increased to $4.3 million from $2.8 million in the prior-year period, with contributions from teleradiology, imaging systems, OEM services, AI, software and Health IT. Nanox has secured FDA clearance for Nanox.ARC, Nanox.ARC X and three Nanox.AI medical imaging solutions, while its commercial and clinical activities involve organizations including RadNet, Cedars-Sinai, Corewell Health and Brigham and Women’s…

MondayAug 24, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase

Following completion of the initial phase of its collaboration with OmniAb, VERAXA will engineer the final VXA-222 candidate and conduct the preclinical validation needed to determine the program’s next development steps. VXA-222 uses an “AND-gate” approach designed to recognize two tumor-associated antigens simultaneously before delivering its therapeutic payload. The company has separately filed its first patents related to its BiTAC-TCE and BiTAC-ADC platforms while expanding protection around antibody conjugation and payload technologies. The company is building a diversified oncology pipeline spanning bispecific T-cell engagers, ADCs, and other engineered antibody formats. VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel…

FridayAug 21, 2026 10:00 am

Researchers Test Simple Fix That Saves Time Spent in ERs

A new study has confirmed that a simple fix in the way patients are treated in emergency rooms (ERs) can speed up care and reduce the amount of time patients wait before being attended to. The fix involves treating selected patients while they are seated instead of waiting for an ER bed to become available so they can be attended to. The study, whose findings appeared in the journal Management Science, sought to find a way to speed up patient care without compromising the quality of care delivered. The researchers started their work by looking at the biggest bottleneck ERs face: the lack of enough beds at these medical facilities. They observed that beds are in short supply and…

FridayAug 21, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision

VERAXA Biotech is changing how antibody-based therapies recognize and attack cancer cells, developing antibody-based cancer therapies with an emphasis on bispecific antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”). Its proprietary BiTAC platform uses a dual-targeting, “AND-gated” architecture designed to activate therapeutic effects preferentially at tumor sites. The company has advanced its lead BiTAC-TCE toward IND/CTA-enabling activities following cell-line development work and regulatory feedback from Germany’s Paul-Ehrlich-Institute. VERAXA’s VXA-222 bispecific ADC has moved beyond the initial discovery phase following completion of the antibody-discovery step with OmniAb. The company reported more than 50 granted owned or exclusively licensed patents across 26 patent…

ThursdayAug 20, 2026 10:00 am

Former Adviser to Fauci Pleads Guilty to Covid-Related Conspiracy Charge

Dr. David Morens, formerly an adviser to Anthony Fauci during the Covid-19 pandemic, has pleaded guilty to a charge of conspiracy to conceal information about the pandemic. The charge focuses on attempts to conceal documents of the government by evading laws that allow members of the public to access records in the possession of the government. The particulars of the charge brought against Morens in a Maryland federal court indicate that he undertook to conceal information about a research grant to a Chinese entity that had been identified as a possible origin of the pandemic. Morens, aged 78, was indicted in April this year after prosecutors…

WednesdayAug 19, 2026 10:30 am

Earth Science Tech Inc. (ETST) Continues Steady Growth with Acquisition of California-Based Compounding Pharmacy

Earth Science Tech, an expanding health-based holding company, recently announced the acquisition of Meduvo LLC, a compounding pharmacy that currently operates from a 2,000-square-foot facility in La Verne, California The acquisition grows the company’s network to 34 jurisdictions in the United States and establishes a strategic West Coast operational hub In addition to Meduvo, ETST also operates other compounding pharmacies through its specialized subsidiaries RxCompoundStore.com LLC (“RxCS”) and Mister Meds LLC Earth Science Tech (OTC: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine sector, recently acquired Meduvo LLC, a compounding pharmacy. Meduvo currently operates from a 2,000-square-foot…

WednesdayAug 19, 2026 9:00 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves

MS drug development is increasingly expanding beyond controlling inflammation toward approaches designed to protect the nervous system and address mechanisms underlying progressive disability. Remyelination and protection of existing myelin remain major unmet needs in MS, as no approved therapy has established the ability to restore previously damaged myelin. Quantum BioPharma’s Lucid-MS is a patented new chemical entity designed to inhibit demyelination and protect myelin without suppressing the immune system. The U.S. FDA has cleared Quantum BioPharma to proceed with its planned phase 2 clinical trial of Lucid-MS in people with multiple sclerosis. Multiple sclerosis (“MS”) treatment has traditionally focused on…

TuesdayAug 18, 2026 10:00 am

Researchers Identify a Protein That Could Be Targeted in Glioblastoma Therapy

Glioblastoma is very difficult to treat because it quickly adapts and evolves to become resistant to existing treatments indicated for brain cancers. Now, scientists have found a protein on this cancer’s cells that could be targeted in order to make the cancer more vulnerable to the treatments administered to combat this deadly malignancy. The discovery was made by researchers based at the Comprehensive Cancer Center at Ohio State University. The findings of this preclinical study appeared in the journal Cancer Letters. The team wanted to find a way to make existing treatments like chemotherapy and radiotherapy more effective against this…

FridayAug 14, 2026 10:30 am

Earth Science Tech Inc. (ETST) Seeks to Implement a Unified Strategy to Unlock True Market Value and Support Shareholders

Earth Science Tech seeks to implement a unified strategy aimed at maximizing shareholder value, resolving structural hurdles, and elevating corporate governance The company will hold a virtual annual meeting on August 31, 2026, during which shareholders will vote on key initiatives that will position ETST for an uplisting to a higher-tier exchange, eliminate the structural barriers that hinder the infusion of institutional capital, and prevent stock dilution These initiatives are informed by extensive dialogue between shareholders and management leading to a consensus that the company’s current market valuation simply does not accurately reflect its financial success or future potential The…